Introduction
============

In daily dental practice it is common to treat the patients being intervened with oral anticoagulants in order to prevent or treat thromboses. Patients receiving oral anticoagulants have a greater risk of haemorrhage during odontological treatments.

Classically, they were treated exclusively with dicumarinic anticoagulant agents, among which are warfarin and acenocumarol ([@B1]), but the disadvantages of these anticoagulants is that their dose must be adjusted specifically for each patient; they interact with many other drugs and with certain foods, and their use requires periodic monitoring using the International Normalized Ratio (INR) ([@B2]).

Current research in the field of antithrombotic agents focuses on seeking the ideal oral anticoagulant that will overcome some of the pitfalls of classic oral drugs. Thus, in recent years new anticoagulant agents have appeared, among which are apixaban, riva-roxaban and dabigatran. These new generation drugs do not require periodic laboratory-supervised monitoring and interact less with other drugs and foods ([@B3],[@B4]). However, their use in comparison with traditional oral anticoagulants involves economic costs ([@B5],[@B6]).

On 20 September 2012 The European Medicines Agency (EMA) authorized the use of apixaban for the prevention of ictus and systemic clots in adult patients with non-valvular atrial fibrillation who had one or more of the following risk factors: ictus or transient ischaemic attack, an age of 75 or above, arterial hypertension, diabetes mellitus and symptomatic cardiac insufficiency equal to or greater than class 2 on the New York Heart Association (NYHA) scale ([@B7]). The commercial name of apixaban is Eli-quis®.

Apixaban acts by inhibiting the coagulation factor Xa, indirectly inhibiting the platelet aggregation induced by thrombin. It prevents the formation of thrombin and hence clot formation. In comparison with classic dicumarinic anticoagulants, it inhibits vitamin K-dependent coagulation factors.

The drug is absorbed rapidly and its maximum concentrations are reached at 3-4 hours after administration. Its binding to human plasma proteins is approximately 8% and it has a half-life of 8-15 hours. It is mainly metabolized by cytochrome CYP3A4/5; approximately 25% of the drug is eliminated by the kidney and 27% in urine. The plasma levels of the drug mainly depend on the dose administered and little variation is observed between individuals ([@B8],[@B9]).

Currently, there is no antidote to haemorrhages induced by apixaban administration ([@B10]). Protamine, vitamin K or plasma transfusions do not affect its anticoagulant effect ([@B11],[@B12]).

Material and Methods
====================

In the present contribution we offer an exhaustive review of the literature found in the ISI Web of Knowledge, PubMed, Scopus and Cochrane Library in November 2015, including articles published in the last 10 years in English and Spanish. The words used were "apixaban", "rivaroxaban", "dabigatran", "new oral anticoagulants", "dental treatment" and "dental implications" with the "and" boolean operator. Metaanalyses, systematic reviews, clinical trials and case-control studies were considered. Specialized textbooks were also consulted.

Results
=======

Laboratory tests are available that allow the plasma levels of apixaban to be determined but they are not in wide use and are expensive. Currently, there is no scientific evidence to be able to establish a relationship between the duration of laboratory tests and the likelihood of the occurrence of haemorrhages in patients undergoing treatment with apixaban ([@B13]). Among the tests whose results may be altered by apixaban are chromogenic assays to assess anti-factor Xa activity, the prothrombin time and the activated partial thromboplastin time.

-Chromogenic assays to assess anti-factor Xa activity: Anti-factor Xa activity is directly related to the plasma concentration of apixaban. Maximum values are reached with the maximum plasma concentrations of the anticoagulant ([@B14],[@B15]).

-Prothrombin time: An increase is seen in the prothrombin time, depending on the plasma concentration in the patients taking apixaban. This increase in the prothrombin time has minimal effects ([@B16]).

-Activated partial thromboplastin time: The increase in the activated partial thromboplastin time is insignificant. Like the prothrombin time, this time is not suitable for measuring the effect of apixaban ([@B17]-[@B20]).

Certain dental treatments that involve a risk of haemorrhage may require temporal interruption of apixaban administration. It is thus of great importance to plan invasive dental treatments entailing a risk of haemorrhage ahead. When dealing with a patient receiving oral anticoagulants, it is necessary to judge the risk of haemorrhage in the dental procedure and the risk of thrombosis arising from the patient's underlying pathology.

The risk of thrombosis in a patient is gauged by the attendant physician and there are several factors that may govern such risk.

The suspension or not of apixaban and the actual moment of withdrawal depend on the risk of haemorrhage involved in the intervention. It is crucial to know the renal status of the patient to evaluate the moment when the drug is to be suspended ([@B21]). The specialist physician will make the decision about whether the drug should be withdrawn or not ([@B22]).

In comparison with the new oral anticoagulants, traditional drugs have aroused considerable controversy regarding suspension of the anticoagulant prior to dental procedures ([@B23]).

Depending on the risk of haemorrhage of the dental procedure it is possible to classify dental treatments in two groups: procedures with a low risk of haemorrhage and procedures with medium and high risks of haemorrhage.

-Invasive procedures with a low risk of haemorrhage: Considering the low risk of haemorrhage and the half-life of the drug it is not necessary to withdraw treatment with apixaban, with the exception of the dose scheduled for the day on which the dental treatment is to be carried out. The procedure should be performed 12 hours after the last administration of apixaban or at 24 hours if a dose is missed. Low-risk procedures include simple tooth extractions, oral surgery lasting less than 45 minutes and mucogingival surgical procedures (if the haemorrhage is not very extensive). Before performing an invasive procedure, if there has been a previous process of inflammation the risk of haemorrhage will be greater.

Most dental interventions are considered invasive but with a low risk of haemorrhage, such that the suppression of apixaban prior to dental treatment is not necessary. However, to date there are no scientific studies that support such an assertion owing to the short time that this anticoagulant has been available ([@B24]).

-Invasive procedures with a medium and high risk of haemorrhage: Within this group, treatment with apixaban must always be withdrawn. The drug should be suspended at least 24 hours previously in the case of medium risk and at least 48 hours in cases of high risk. Owing to the short withdrawal time, no replacement therapy with low molecular weight heparin is necessary. If the period of drug suspension is prolonged, the administration of low-molecular weight heparin is recommended ([@B24]-[@B26]).

In invasive dental procedures with a low risk of haemorrhage and a medium or high risk if the patient has an altered kidney function, the time of apixaban suspension should be extended ([Table 1](#T1){ref-type="table"}). The extraction of more than three teeth at once is considered a medium-high risk procedure, as is the case of oral surgical procedures lasting more than 45 minutes ([@B23]-[@B27]). In this group, the specialist physician must counsel the withdrawal of apixaban administration.

Table 1Guide to the suppression of apixaban.

Both in procedures with a low risk of haemorrhage and in those with a medium or high risk, local haemostatic measures must be taken ([@B28]-[@B33]).

Once the dental intervention has been completed, the time when apixaban treatment should be reinstated is determined by the risk of haemorrhage involved in the invasive procedure performed ([Table 2](#T2){ref-type="table"}) ([@B30]-[@B33]).

Table 2Guide to the reinstatement of treatment with apixaban.

Conclusions
===========

Patients undergoing treatment with oral anticoagulants have a greater risk of haemorrhaging when receiving invasive dental treatments.

In view of the drawbacks of the classic dicumarinic anticoagulants detected in recent years, new oral anticoagulants have been developed, among which is apixaban. The advantages of these new anticoagulants are as follows: they have predictable pharmacokinetics, they exhibit fewer interactions with drugs and foods, no periodic analytical controls are required and their half-life is shorter. The main drawback is the absence of an efficient antidote if haemorrhages appear.

Clinical experience with the new anticoagulants in dentistry is very limited, but it is to be expected that treatment with these new oral drugs will increase in the future. As health professionals we must be aware of the existence of these new oral anticoagulants and must be ready to report the possible appearance of secondary effects to the pertinent authorities. Finally, protocols must be developed based on the scientific evidence in order to know how these patients should be handled from the point of view of dental interventions.
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